Close Menu

The ability to detect low levels of circulating tumor DNA (ctDNA) can be significantly improved by first analyzing mutations identified through tumor genotyping, according to a new study in Science Translational Medicine. While ctDNA has proven useful for noninvasive cancer monitoring, detecting this genetic material in patients with low-volume or residual disease remains challenging.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.